Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report
Triatop — sponsor report · 2018 · KI-THYM-001, Phase III report; permit 85, 26 February 2018
Reported findings and study design
Open randomized active-comparator allergy study; 72 randomized (36/36); one comparator withdrawal. Thymodepressin nasal spray versus standard care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Primary nasal-symptom comparison | p=0.6708; no significant between-group difference. | Day 16 |
| Selected secondary symptoms and sleep | Some comparisons favored treatment; these do not overturn the neutral primary outcome. | |
| Drug-related adverse events | Reported in both groups; exact counts not extracted; comparison p=1. | |
| Later follow-up | Day 47±2, approximately 30 days after therapy. |
Superiority and noninferiority are not established. The report-date inconsistency and unsigned fields require a final-version check.
Source for the extracted data ↗ · Checked 2026-11-06
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Open active-comparator design; nonsignificance does not establish noninferiority.
- Report dated 8 October 2018 precedes the listed 20 October study end; signed final version needs authentication.
- Allergy study, separate from rheumatoid-arthritis protocol ИБХ-ТД01.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Sponsor-hosted report PDF and companion HTML
Review depth: Selected report text, pp.24–25, 60–61, 75–80; no visual verification or annex review
Related-report group: ki-thym-001-2018. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original report text and companion HTML checked. Investigators: A. A. Odegova, A. A. Bagretsova, K. I. Lobanov, A. F. Pyankov and M. G. Omelyanenko.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Sponsor clinical-study report; not a journal publication
Citation and original source
Original source: Triatop — sponsor report. Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report KI-THYM-001, Phase III report; permit 85, 26 February 2018 2018.
Molekul research summary: https://molekul.io/research/thymodepressin-rhinoconjunctivitis-2018-csr. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry